<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963920</url>
  </required_header>
  <id_info>
    <org_study_id>S18</org_study_id>
    <nct_id>NCT04963920</nct_id>
  </id_info>
  <brief_title>A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock</brief_title>
  <acronym>PROCYSS</acronym>
  <official_title>A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents Europe GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with&#xD;
      vasoplegic septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in noradrenaline (NA) dose 24 hours after baseline, assessed as mean over the time window 22 to 26 hours after baseline</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>SoC+CytoSorb treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients allocated to this group will receive only standard of care therapy according to applicable guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cytosorb® 300 ml</intervention_name>
    <description>patients wiil receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines</description>
    <arm_group_label>SoC+CytoSorb treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated with standard therapy according to guidelines for sepsis&#xD;
&#xD;
          -  Vasoplegic septic shock*, requiring NA ≥ 0.3 µg/kg/min despite adequate fluid&#xD;
             resuscitation to maintain MAP ≥ 65 mmHg after at least 6 hours of guideline-oriented&#xD;
             initial therapy&#xD;
&#xD;
          -  Standard of care (SOC) shock treatment for &gt;6 and &lt; 24 hours&#xD;
&#xD;
          -  Serum lactate &gt;2 mmol/l at screening&#xD;
&#xD;
          -  IL-6 ≥ 1000 ng/l at screening&#xD;
&#xD;
          -  Indication for CRRT according to:&#xD;
&#xD;
        Kidney Disease Improving Global Outcomes (KDIGO) stage 2 AND/ OR Severe refractory&#xD;
        metabolic acidosis after fluid resuscitation (HCO3&lt;20 mmol/l and pH &lt;7.20)9&#xD;
&#xD;
          -  Minimum 18 years of age&#xD;
&#xD;
          -  Provide voluntary consent to participate in the study either directly or via a legally&#xD;
             authorized representative (LAR) or in accordance to the procedure after determination&#xD;
             of an emergency situation according to § 21 no. 3 sentence 3 MPG, as applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an abdominal source of infection without a source control intervention&#xD;
             within 6h of the determination of the indication OR a planned additional surgical&#xD;
             intervention outside of ICU within the first 48 hours&#xD;
&#xD;
          -  Patients with abdominal source of infection due to anastomotic leakage&#xD;
&#xD;
          -  Septic shock for more than 24 hours prior to inclusion&#xD;
&#xD;
          -  Need for use of first-line vasopressors other than NA&#xD;
&#xD;
          -  Patients with a steroid therapy above Cushing-threshold dose (e.g. 30 mg&#xD;
             hydrocortisone/d or 6 mg prednisolone/d) for more than 30 days prior to baseline&#xD;
&#xD;
          -  Cytokine-specific antibody therapy before inclusion&#xD;
&#xD;
          -  Anticipated interruption of CRRT and / or CytoSorb® 300 mL device therapy for more&#xD;
             than 2 hours within the first 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf (UKE)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Giersdorf, PhD</last_name>
    <phone>+49 (0) 30 765 84 66 33</phone>
    <email>clinical@cytosorbents.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antje Fechner</last_name>
    <phone>+49 (0) 30 765 84 66 33</phone>
    <email>clinical@cytosorbents.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stefan Kluge, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

